Cambium Bio (@cambiumbio) header
Cambium Bio (@cambiumbio) profile picture

Cambium Bio $CMB.AX is a clinical-stage therapeutics company focusing on the development of innovative #biologics for #ophthalmology and tissue #regeneration

Sydney, Australia
Joined May 2023
🧬 Cambium Bio ($cmb.ax) has secured a A$10.85M funding package to initiate the pivotal Phase 3 trial of Elate Ocular®, a potential first-in-class biologic for dry eye disease. 💰 A$7.1M placement from strategic shareholders, led by ZYBT, at A$0.48/share, a premium to market. Our 4th consecutive raise priced at a premium. Plus A$3.75M non-dilutive R&D Tax Incentive pre-financing. 🧪 CAMOMILE-2: single 475-patient pivotal trial, FDA-confirmed as sufficient for a BLA. Trial start targeted Q4 2026. 👁️ Topline late 2027. BLA filing 2028, subject to hitting co-primary sign and symptom endpoints. No biologic has ever been approved for dry eye disease.
1
2
20
Our 30 June 2026 quarterly report is out. 🔬 CAMOMILE-2 Phase 3 finalised: 515 patients, 475 evaluable completers 📄 IND amendment to FDA, no objection ✅ Ethics approved AU and US 📅 First Patient In targeted Q4 CY 2026, subject to funding Announcement in comments. $CMB.AX
1
1
48
🚨 Cambium Bio (ASX: $CMB) lodges June Qtr 4C ✅ FDA green light for Phase 3 Elate Ocular® ✅ Ethics approvals in 🇺🇸 + 🇦🇺 ✅ Dosing starts Q4 CY 2025 ✅ Top-line data Q4 CY 2026 💰 A$2.12M raised at 60% premium 📄 Details 👇
77
🚀 Cambium Bio (ASX:CMB) secures A$2.12 M via a fully-subscribed placement led by 🇹🇼 Da Jyun Capital. 🔬 Issue price A$0.4637/sh (~60 % premium). 💸 Proceeds power registration-enabling Phase 3 trials of Elate Ocular® for dry eye, with first dosing targeted for 2025. 🙌 Thanks to all supporters! $CMB
291
🚨 Clinical milestone alert! Cambium Bio has received ethics approvals in 🇦🇺 Australia (Bellberry HREC) and 🇺🇸 the US (@advarra IRB) for our pivotal Phase 3 trials of #ElateOcular in #DryEyeDisease. 👁️‍First patient: Oct 2025 📊 Top-line data: Q3 2026 📎 Details below 👇 #Biotech #Ophthalmology #ClinicalTrials #ASX $CMB
1
161
Meet with us at BIO2025, June 16-19 in Boston! Let’s collaborate through the BIO Partnering system—because the world can’t wait. #BIO2025
23
🚀 2024 Year in Review - A transformative year for $CMB! ✨ Completed strategic merger 💰 Raised A$6.5M 🏆 FDA Fast Track designation for Elate Ocular® 👥 Strengthened Board & Scientific Advisory team 🔬 Phase 3 trials on track for Q2 2025 Watch CEO Year in Review video 👇
1
93
🔬 Exciting News: Cambium Bio Limited (ASX:CMB) Strengthens Board with Appointment of Distinguished Ophthalmologist We're delighted to announce the appointment of Clinical A/Prof. Chandra Bala, MBBS, PhD, to our Board of Directors. A/Prof. Bala brings extensive expertise in cataract, cornea, and refractive surgery, along with significant experience in Phase 2-4 ophthalmic clinical trials. As a senior partner at PersonalEyes and cornea surgeon at Macquarie University Hospital, A/Prof. Bala's clinical insights will be invaluable as we advance our lead candidate Elate Ocular® through Phase 3 trials for dry eye disease. "Having treated numerous individuals struggling with dry eye disease, I am excited by the potential of Elate Ocular to address the limitations of current therapies," said A/Prof. Bala. Welcome to the Cambium Bio team, A/Prof. Bala! 🤝 #Biotech #Ophthalmology #DryEye $CMB
47
CEO Karolis Rosickas presenting Cambium Bio's (ASX:CMB) Phase 3-ready Elate Ocular programme at AusBioInvest 2024. Excited to share our progress in regenerative medicine and plans to address the US$2B+ dry eye disease market. Thanks @AusBiotech for hosting! 🧬👁️ $CMB #AusBio #AusBioInv
1
4
199
Come to see our CEO @rosickas presenting at AusBioInvest 2024 in Melbourne today! #AusBioInv
1
3
158
📢 Exciting Update from Cambium Bio $CMB! We're thrilled to announce the release of our updated Corporate Presentation, featuring our latest clinical development plan for Elate Ocular®, our innovative dry eye disease treatment. 🔑 Key highlights: 🧬 Proprietary Aurarix® FD-HPL technology platform 👁️ Elate Ocular® - our lead product for dry eye disease 📊 Impressive Phase 1/2 clinical data 🏗️ Detailed Phase 3 trial design 📅 Updated timeline for key milestones Our registration-enabling Phase 3 programme includes: 🔬 Two randomized clinical trials (CAMOMILE-2 and CAMOMILE-3) 👥 370 patients each 🌎 Sites in USA, Australia, and Taiwan Next steps: 💉 GMP drug manufacturing: Dec 2024 - Feb 2025 🚀 Phase 3 trial initiation: Mar/Apr 2025 📊 Topline data expected: Mid-2026 Access the full presentation: cambium.bio/Investors-and-Me…
29
📢 Exciting news from Cambium Bio (ASX:CMB)! Our CEO, Karolis Rosickas, has demonstrated strong confidence in our company's future by acquiring additional shares in the open market. Key highlights: 📈 38,717 new shares acquired 💼 Total shareholding now 77,080 shares (≈0.65% of outstanding share capital) 🧬 Underscores belief in our proprietary technologies, including Elate Ocular® 💬 "My decision to increase my personal shareholding reflects my belief in Cambium Bio's potential to deliver significant value to patients, clinicians, and shareholders alike," said Mr. Rosickas. "With our lead product, Elate Ocular®, advancing into Phase 3 trials, we are well-positioned to address the substantial unmet needs in dry eye disease and beyond." For full details, please see the attached ASX announcement. #ASX #dryeye #ophthalmology $CMB
1
106
Big news! Cambium Bio $CMB welcomes two key appointments: - Dr. Louis Tong to Scientific Advisory Board Expert in ocular immunology & dry eye disease - Dr. ChiTai Chang to Board of Directors Pharma industry veteran & strategic leader Boosting our expertise as we advance Elate Ocular® for dry eye disease. Full details in ASX announcement ⬇️ #Ophthalmology #ASX
1
106
Cambium Bio $CMB releases FY2024 Annual Report, highlighting: - Successful merger with Cambium Medical Technologies - Elate Ocular® advancing to Phase 3 trials - $3.48M raised from strategic investors - Royalty income from ZYBT partnership Read the full report: buff.ly/3TfIxoS #Biotech #ASX #AnnualReport
1
4
92
🚀 Q4 2024 Update: Cambium Bio ($CMB) hits major milestones! ✅ Merger completed ✅ Elate Ocular® progressing to Phase 3 ✅ A$3.48M raised ✅ Leadership team expanded 🎥 Watch our CEO break down the numbers and share our vision for the future! #BioTech #InvestorUpdate #DryEye
1
1
1
66
$CMB Shareholders: Important update! Read our latest ASX announcement on the General Meeting results and watch our CEO's video message on the successful capital raise and next steps for Elate Ocular. buff.ly/4cmYq4s
1
1
89